Samstag, 17. April 2021
Navigation öffnen
Anzeige:
Piqray
Piqray
JOURNAL ONKOLOGIE – STUDIE
ADAM

Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Rekrutierend

NCT-Nummer:
NCT04295447

Studienbeginn:
Dezember 2020

Letztes Update:
05.01.2021

Wirkstoff:
Apalutamide 60Mg Tab

Indikation (Clinical Trials):
Prostatic Neoplasms

Geschlecht:
Männer

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Westfälische Wilhelms-Universität Münster

Collaborator:
Janssen Pharmaceutica N.V., Belgium

Studienleiter

Martin Bögemann, Univ.-Prof. Dr. med.
Principal Investigator
Universitätsklinikum Münster, Klinik für Urologie und Kinderurologie

Kontakt

Martin Bögemann, Univ.-Prof. Dr. med.
Kontakt:
Phone: adam@ukmuenster.de
E-Mail: martin.boegemann@ukmuenster.de
» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Studien-Informationen

Brief Summary:

The primary objective of this trial is to determine if adjuvant apalutamide in prostate

cancer patients at high risk of developing subsequent metastatic disease results in prolonged

biochemically recurrence-free survival after radical prostatectomy (RPE) in comparison to

standard of care (SOC).

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Signed informed consent form (ICF).

2. Men ≥ 18 years of age.

3. Patients with histologically confirmed adenocarcinoma of the prostate after radical

prostatectomy.

4. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1.

5. Exclusion of metastatic disease by CT-scan of thorax and abdomen (MRI of abdomen is

possible) and bone scan prior to radical prostatectomy.

6. Patients after radical prostatectomy must meet the d'Amico criteria for high risk of

disease recurrence: i.e. one of the following after RPE: 1) Gleason score ≥8, any

T-stage, any initial PSA (iPSA) or 2) Gleason score 6 or 7, any iPSA and ≥pT2c or 3)

iPSA >20 ng/ml, any Gleason score, any T-stage.

7. Patients have to have recovered from radical prostatectomy within four weeks to be

able to take part in the study.

8. PSA-value must have declined below 0.2 ng/ml prior to randomization

9. Adequate hematologic, hepatic, and renal function:

Hematologic

- Haemoglobin ≥9.0 g/dL independent of transfusions

- Neutrophils ≥1.5 Ths./µL

Hepatic:

- Total bilirubin ≤1.5X upper limit of normal (ULN) [except for subjects with

documented Gilbert's disease in which case total bilirubin not to exceed 10X ULN]

- Alanine (ALT) and aspartate (AST) aminotransferase ≤2.5X ULN

Renal:

- Serum creatinine <1.5X ULN or calculated creatinine clearance ≥50 mL/min

- Serum potassium ≥3.5 mM

- Serum albumin ≥ 3.0 g/dL.

10. Ability to swallow study medication tablets.

11. In case of apalutamide treatment: Agrees to use a condom and another highly effective

method of birth control if he is having sex with a woman of childbearing potential or

to use a condom if he is having sex with a woman who is pregnant

Exclusion Criteria:

1. Any chronic medical condition requiring a higher dose of corticosteroid than 10mg

prednisone/prednisolone q.d.

2. Prior cytotoxic chemotherapy or biologic therapy for the treatment of prostate Cancer.

3. Prior or current treatment of prostate cancer with apalutamide, enzalutamide,

darolutamide, or other investigational agents targeting the androgen receptor.

4. Prior therapy with Sipuleucel-T or other vaccination or immunogenic therapy for the

treatment of prostate Cancer.

5. Prior treatment with abiraterone acetate or other androgen synthesis inhibitors (e. g.

ketoconazole, TAK700, TOK001).

6. Use of 5-α reductase inhibitors (eg, dutasteride, finasteride) ≤4 weeks prior to

randomization.

7. Prior surgical castration or medical castration using LHRH-Agonists or

GnRH-Antagonists.

8. Prior or current radiation or radionuclide (including radium-223 dichloride) therapy

for treatment of prostate cancer (adjuvant radiation of the prostate bed without

involvement of the regional lymph node template as by standard of care in case of

positive surgical margins (R1) is allowed).

9. Prior or current systemic treatment with an azole drug (e.g. fluconazole,

itraconazole) within 4 weeks of Cycle 1, Day 1.

10. Any lymph node or distant metastasis.

11. History of seizure or condition that may predispose to seizure (including, but not

limited to prior stroke, transient ischemic attack or loss of consciousness ≤1 year

prior to randomization; brain arteriovenous malformation; or intracranial masses such

as schwannomas and meningiomas that are causing edema or mass effect).

12. Current or prior treatment with anti-epileptic medications for the treatment of

seizures.

13. Management of cardiovascular risk factors, such as hypertension, diabetes or

dyslipidaemia should be optimised as per standard of care before treatment with

apalutamide will be initiated

13.1. Uncontrolled hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg. For

patients with relevant comorbidities (e.g. diabetes) systolic BP ≥130 mmHg or

diastolic BP ≥80 mmHg). Patients with a history of hypertension are allowed provided

that blood pressure is controlled by anti-hypertensive Treatment

13.2. Patients with uncontrolled diabetes defined as HbA1c ≥7.5%

13.3. Patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl

13.4. Cardiovascular risk assessment via an appropriate score (e.g. the SCORE-Chart

for the European high/low risk score from the European Society of Cardiology) and ≥

borderline risk i.e. 10% of developing cardiovascular events within 10 years without

prior established cardiovascular disease

14. Active or symptomatic viral hepatitis or chronic liver disease or HIV.

15. History of pituitary or adrenal dysfunction.

16. Clinically significant heart disease as evidenced by myocardial infarction, or

arterial thrombotic events in the past 6 months, severe or unstable angina, or New

York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction

measurement of <50% at baseline.

17. Any condition that requires treatment with digoxin, digitoxin, and other digitalis

drugs.

18. Long QT-Syndrome.

19. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy.

20. Other malignancy with a ≥30% probability of recurrence within 24 months, except

non-melanoma skin Cancer.

21. Any condition, which, in the opinion of the investigator, would preclude participation

in this trial.

22. Gastrointestinal conditions affecting Absorption.

23. Hypersensitivity to the active substance, or to any of the excipients of the study

medication.

24. Any psychological, cognitive, familial, sociological or geographical condition that,

in the investigator's opinion, compromises the patient's ability to understand the

patient information, to give informed consent or to comply with the study protocol.

25. Participation in another interventional clinical trial during this trial or within 4

weeks before entry into this trial. There may be exceptions at the discretion of the

(coordinating) investigator.

Studien-Rationale

Primary outcome:

1. Progression-free survival (PFS). (Time Frame - From date of randomization until the date of first documented progression (BCR or metastases) or date of death from any cause, whichever came first, assessed up to 7 years"):
This endpoint is defined as time interval from randomization until BCR (irrespective of the PSADT), metastases, or death from any cause, whichever occurs first. BCR is defined as a PSA ≥ 0.2 ng/ml that has risen on at least two separate occasions at least four weeks ± 3 days apart and measured by the central PSA-lab. The time of BCR is then backdated to the time of the first increased PSA measurement. Metastatic disease will be defined as the presence of bone metastases visualized on bone scan prostate cancer working group 3 (PCWG3)-criteria; and/or visceral (e.g. liver, lung, brain) or extra-pelvic nodal metastases visualized on CT scan (or MRI scan) (RECIST 1.1-criteria). Evaluations will be performed every 6 months once BCR occurred or sooner if clinically indicated. For a patient with none of these events before the end of follow-up, observation of PFS will be censored at the date of his date of last contact.



Secondary outcome:

1. PSA doubling time (PSADT) (Time Frame - If BCR occurs up to 6 months later):
In case of a BCR, PSA kinetics as the PSADT are calculated based on the monthly PSA measurements during the first six months after the BCR. The values used to determine the BCR are included in the calculation of PSA kinetics as well. PSADT is calculated according to Pound et al. by the natural log of 2 (0.693) divided by the slope of the relationship between the log of PSA and time of PSA measurement (i.e. time from BCR) for each patient [33]. PSADT can also be assessed using the MSKCC PSADT calculator (https://www.mskcc.org/nomograms/prostate/psa_doubling_time) using the above definitions.

2. Incidence of Adverse Events [Safety and Tolerability] (Time Frame - From date the informed consent is signed until BCR occured and PSADT was calculated or when distant metastasis occurred (both with or without BCR) or date of death from any cause, whichever came first, assessed up to 7 years.):
Safety and tolerability assessed on the basis of adverse events, more precisely adverse events, serious adverse events, adverse reactions, and serious adverse reactions

Studien-Arme

  • Other: Standard of care
    Observation only or An optional adjuvant radiation of the prostate bed in case of positive surgical margin
  • Experimental: Apalutamide
    30 cycles apalutamide 240 mg (4 x 60 mg) once daily on days 1-28 of a 28-day cycle in addition to standard of care

Geprüfte Regime

  • Standard of care:
    Observation only or An optional adjuvant radiation of the prostate bed in case of positive surgical margin
  • Apalutamide 60Mg Tab:
    (4 x 60 mg) once daily on days 1-28 of a 28-day cycle

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Weltgesundheitstag 2021: Das BürgerTelefonKrebs informiert im Kampf gegen Krebs
Weltgesundheitstag+2021%3A+Das+B%C3%BCrgerTelefonKrebs+informiert+im+Kampf+gegen+Krebs
©Antonioguillem - stock.adobe.com

Die Medien und das Internet überfluten uns regelmäßig mit Informationen zu unzähligen Erkrankungen und Anleitungen für einen gesunden Lebensstil. Doch diese Inhalte ersetzen weder die individuelle Beratung, noch wichtige Vorsorgeuntersuchungen. Im vergangenen Jahr haben viele Bürger:innen die empfohlenen Check-ups vernachlässigt und den als nicht so wichtig empfundenen Gang zur Ärztin oder zum Arzt...

Online-Meeting zum Thema Selbstuntersuchung
Online-Meeting+zum+Thema+Selbstuntersuchung
©underdogstudios / Fotolia.de

So eine Einladung bekommen die Fortuna-Frauen wohl nicht alle Tage: Die Selbsthilfe-Initiative ISI e.V. mit Sitz am Luisenkrankenhaus lud zusammen mit Fortuna Düsseldorf (beide verbindet seit 8 Jahren eine soziale Partnerschaft) die Fortuna-Damen aber auch interessierte Männer zu einem ganz besonderen digitalen Meeting ein, das für die Selbstabtastung der Brust sensibilisieren sollte. Dr. med. Maren Darsow, Chefärztin im...

Vom Telemedizin-Netzwerk bis zur Ersthelfer-App: Medizintrends mit Zukunft

Die Deutschen werden immer älter. Chronische Leiden wie Demenz oder Herz-Kreislauf-Erkrankungen stellen künftig das Gesundheitssystem auf die Probe. Medizinforscher und Gesundheitsexperten aller Branchen arbeiten längst unter Hochdruck an neuen Lösungen für die Gesundheitsversorgung von morgen. In die Karten spielen ihnen dabei die Digitalisierung und der Trend zur Vernetzung im Gesundheitswesen. Das zeigt auch der Wettbewerb...